Safety Assessment of Icotinb in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study

Trial Profile

Safety Assessment of Icotinb in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Betta Pharmaceuticals Co Ltd
  • Most Recent Events

    • 26 Dec 2014 According to ClinicalTrial.gov record, planned End Date changed from 1 May 2015 to 1 Jun 2016.
    • 26 Dec 2014 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Feb 2015 to 1 Dec 2015.
    • 26 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top